

Author Index Volume 22 (2013)

The issue number is given in front of the pagination

- Abdelhafez, T.H., see Tabll, A. (3,4) 55–65
Abdolalizadeh, J. (1,2) 1–8
Abdolalizadeh, J., see Maleki, L.A. (3,4) 67–71
Aghebati-Maleki, L., see Shahneh, F.Z. (1,2) 15–19
Akbari, A.M. (1,2) 1–8
- Babkin, I.V., see Tyumentseva, M.A. (1,2) 31–49
Baradaran, B. (1,2) 1–8
Baradaran, B., see Maleki, L.A. (1,2) 9–13
Baradaran, B., see Maleki, L.A. (3,4) 67–71
Baradaran, B., see Shahneh, F.Z. (1,2) 15–19
Barton, E., see Roye-Green, K. (3,4) 87–93
- Christensen, C.J., see Wagner, L.A. (1,2) 21–29
- Dawson, J., see Roye-Green, K. (3,4) 87–93
Dunn, D.M., see Wagner, L.A. (1,2) 21–29
- El Abd, Y., see Tabll, A. (3,4) 55–65
El Awady, M., see Tabll, A. (3,4) 55–65
El Din, N.G.B., see Tabll, A. (3,4) 55–65
El Shenawy, R., see Tabll, A. (3,4) 55–65
El-Mohamady, H., see Tabll, A. (3,4) 55–65
- Gleich, G.J., see Wagner, L.A. (1,2) 21–29
- Lebedev, L.R., see Tyumentseva, M.A. (1,2) 31–49
- Majidi, J., see Maleki, L.A. (1,2) 1–8
Majidi, J., see Maleki, L.A. (1,2) 9–13
Majidi, J., see Maleki, L.A. (3,4) 67–71
Maleki, L.A., B. Baradaran, J. Majidi, M. Mohammadian and F.Z. Shahneh, Future prospects of monoclonal antibodies as magic bullets in Immunotherapy (1,2) 9–13
Maleki, L.A., D. Shanehbandi, J. Majidi, M. Yusefi, J. Abdolalizadeh, M. Orangi and B. Baradaran, Production of Anti-CD14 monoclonal antibody using synthetic peptide of human CD14 as immunizing antigen (3,4) 67–71
- Maleki, L.A., J. Majidi, B. Baradaran, J. Abdolalizadeh and A.M. Akbari, Production and characterization of murine monoclonal antibody against synthetic peptide of CD34 (1,2) 1–8
Mc Morris, N., see Roye-Green, K. (3,4) 87–93
Mohammadian, M., see Maleki, L.A. (1,2) 9–13
Morozova, V.V., see Tyumentseva, M.A. (1,2) 31–49
- Naganawa, Y., M. Takeda, M. Shimmoto and H. Shimamoto, Epitope analysis of Japanese cedar pollen allergen Cry j1 with the human monoclonal antibody 4701-1 (3,4) 73–76
- Orangi, M., see Maleki, L.A. (3,4) 67–71
- Perkins, S., see Wagner, L.A. (1,2) 21–29
- Redd, M.J., see Wagner, L.A. (1,2) 21–29
Roye-Green, K., R. Willis, N. Mc Morris, J. Dawson, D. Whittle, E. Barton and M. Smikle, Autoimmune hepatitis in a Jamaican cohort spanning 40 years (3,4) 87–93
- Shahneh, F.Z., B. Baradaran, F. Zamani and L. Aghebati-Maleki, Tumor angiogenesis and anti-angiogenic therapies (1,2) 15–19
Shahneh, F.Z., Current challenges in metastasis: Disseminated and circulating tumor cells detection (3,4) 77–85
Shahneh, F.Z., see Maleki, L.A. (1,2) 9–13
Shahneh, F.Z., Sensitive antibody-based CTCs detection from peripheral blood (1,2) 51–54
Shanehbandi, D., see Maleki, L.A. (3,4) 67–71
Shimmoto, M., see Naganawa, Y. (3,4) 73–76
Shimoto, H., see Naganawa, Y. (3,4) 73–76
Smikle, M., see Roye-Green, K. (3,4) 87–93
Spangrude, G.J., see Wagner, L.A. (1,2) 21–29

- Tabll, A., Y. El Abd, N.G.B. El Din, R. El Shenawy, T.H. Abdelhafez, M. El Awady, H. El-Mohamady and S. Viazov, Establishment of human clones producing neutralizing human monoclonal antibodies to the envelope E1/E2 protein of hepatitis C virus by EBV immortalization of immune CD22⁺ B cells (3,4) 55–65
- Takeda, M., see Naganawa, Y. (3,4) 73–76
- Tikunova, N.V., see Tyumentseva, M.A. (1,2) 31–49
- Tyumentseva, M.A., V.V. Morozova, L.R. Lebedev, I.V. Babkin and N.V. Tikunova, Presence of aberrant V_H 6 domains in anti-interferon- γ autoantibodies in multiple sclerosis (1,2) 31–49
- Viazov, S., see Tabll, A. (3,4) 55–65
- Wagner, L.A., S. Wang, E.A. Wayner, C.J. Christensen, S. Perkins, G.W. Ward, R.B. Weiss, D.M. Dunn, M.J. Redd, G.J. Spangrude and G.J. Gleich, Developing and mature human granulocytes express ELP 6 in the cytoplasm (1,2) 21–29
- Wang, S., see Wagner, L.A. (1,2) 21–29
- Ward, G.W., see Wagner, L.A. (1,2) 21–29
- Wayner, E.A., see Wagner, L.A. (1,2) 21–29
- Weiss, R.B., see Wagner, L.A. (1,2) 21–29
- Whittle, D., see Roye-Green, K. (3,4) 87–93
- Willis, R., see Roye-Green, K. (3,4) 87–93
- Yusefi, M., see Maleki, L.A. (3,4) 67–71
- Zamani, F., see Shahneh, F.Z. (1,2) 15–19